- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.08. | Lobe Sciences Ltd.: Lobe Sciences Announces the Closing of the Previously Announced Private Placement | 347 | ACCESS Newswire | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 14, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company")... ► Artikel lesen | |
| 29.07. | Lobe Sciences Ltd (2): Lobe Sciences arranges private placement | 2 | Stockwatch | ||
| 29.07. | Lobe Sciences Ltd (2): Lobe Sciences hires ArcStone for advisory services | 1 | Stockwatch | ||
| 29.07. | Lobe Sciences Ltd. Engages ArcStone Securities for Strategic Capital Markets Advisory | 367 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases... ► Artikel lesen | |
| 29.07. | Lobe Sciences Ltd.: Lobe Sciences Announces $341,425 CAD Private Placement for General Corporate Purposes | 402 | ACCESS Newswire | NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. ("Lobe Sciences"... ► Artikel lesen | |
| 17.07. | Lobe Sciences Ltd (2): Lobe Sciences issues 546,206 shares for debt of $11,596 | 2 | Stockwatch | ||
| LOBE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 17.07. | Lobe Sciences announces debt settlement | - | Seeking Alpha | ||
| 17.07. | Lobe Sciences Ltd. Announces Debt Settlement | 330 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / July 16, 2025 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved diseases... ► Artikel lesen | |
| 08.07. | Lobe Sciences Ltd (2): Lobe Sciences receives European unitary patent | 1 | Stockwatch | ||
| 08.07. | Lobe Sciences Ltd.: Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease | 636 | ACCESS Newswire | European Unitary Patent EP4117446 Validated - Lobe Sciences secures patent protection in 17 EU member states for its DHA and egg yolk-based composition designed to manage Sickle Cell Disease.Covers... ► Artikel lesen | |
| 18.06. | Lobe Sciences Ltd.: Lobe Sciences Moves Forward with Development of Conjugated Psilocin Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals | 294 | ACCESS Newswire | New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin$6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage clinical... ► Artikel lesen | |
| 03.06. | Lobe Sciences Ltd (2): Lobe Sciences appoints Yao as CFO, EVP | 3 | Stockwatch | ||
| 03.06. | Lobe Sciences Ltd.: Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth | 295 | ACCESS Newswire | Lobe Sciences Ltd. has appointed Mr. Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025, to lead the company's financial strategy during its next phase of growth.Mr.... ► Artikel lesen | |
| 14.04. | Lobe Sciences Ltd (2): Lobe's Cynaptec arranges $6M (U.S.) private placement | 1 | Stockwatch | ||
| 14.04. | Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin | 209 | ACCESS Newswire | Private Placement of US$6 Million to fund additional pre-clinical research, Phase 1 and Phase 2a clinical studiesUS$20 Million additional option included in Private Placement to fund the Phase 3 clinical... ► Artikel lesen | |
| 05.04. | Lobe Sciences Ltd (2): Lobe Sciences issues notes, shares, RSUs | 2 | Stockwatch | ||
| 05.04. | Lobe Sciences Ltd.: Lobe Sciences Provides Corporate Update | 674 | ACCESS Newswire | VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / April 4, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a commercial stage biopharmaceutical company focused... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONXT SOLUTIONS | 0,602 | +1,69 % | BioNxt Solutions Inc.: Semaglutid-API-Lieferung ermöglicht Start der ODF-Entwicklung im Labormaßstab bei BioNxt | VANCOUVER, BC / ACCESS Newswire /
2. September 2025 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE: BNXT)(OTC PINK: XPHYF)(FWB: 4XT) freut sich, den Erhalt
des aktiven pharmazeutischen... ► Artikel lesen | |
| AMYRIS | - | - | Amyris gains sole control of Brazilian fermentation facility | ||
| ATAI LIFE SCIENCES | 3,820 | -1,95 % | Deals im Milliarden-Markt für Psychedelika: AbbVie, Atai Life Sciences, Neural Therapeutics | ||
| SOL GLOBAL INVESTMENTS | 0,032 | -3,64 % | SOL Global Investments Corp.: SOL Global Appoints Hex Trust as Strategic Web3 Partner to Execute Institutional Digital Asset Strategy | Toronto, Ontario--(Newsfile Corp. - August 14, 2025) - SOL Global Investments Corp. (CSE: SOL) (OTCID: SOLCF) (FSE: 9SB) ("SOL Global" or the "Company") on 23 July, 2025, appointed Hex Trust, a leading... ► Artikel lesen | |
| ENTHEON BIOMEDICAL CORP | 0,057 | 0,00 % | Entheon Biomedical Corp.: Entheon Announces Change of Directors | Vancouver, British Columbia--(Newsfile Corp. - April 4, 2025) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) ("Entheon" or the "Company") announces the appointment of Harrison Newlands... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,001 | -93,55 % | Revive Therapeutics Ltd: Revive extends $650,000 private placement | ||
| CYBIN | 5,600 | -2,61 % | Cybin Inc (2): Cybin CEO Drysdale steps down; So appointed in interim | ||
| RAPID DOSE THERAPEUTICS | - | - | Rapid Dose Therapeutics Corp.: Rapid Dose Therapeutics Submits QuickStrip Nicotine Product for Health Canada Approval | Burlington, Ontario--(Newsfile Corp. - August 4, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian life sciences company focused on innovative drug delivery technologies... ► Artikel lesen | |
| BIONTECH | 96,05 | +0,05 % | BioNTech-Aktie springt hoch: "Meilenstein" im Kampf gegen Krebs | Die deutsche Biotech-Gesellschaft BioNTech kommt der ersten Marktzulassung für ein Krebsmedikament wieder ein Stück näher. Am Freitag berichten die Mainzer und der chinesische Partner DualityBio über... ► Artikel lesen | |
| QIAGEN | 40,390 | +0,44 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
| NUVALENT | 80,89 | +1,53 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| DYNE THERAPEUTICS | 14,220 | +7,40 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| EVOTEC | 5,856 | +2,70 % | Evotec-Aktie: Ist das ein wichtiges Signal? | Die Evotec-Aktie bewegt sich weiterhin auf einem sehr niedrigen Niveau; am Montag verbessert sie sich aktuell um +1,5% und steht bei rund 6,10 €. Was bei dem deutschen Biotech-Unternehmen fehlt, sind... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,610 | +1,99 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 50,38 | +3,81 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen |
LOBE SCIENCES LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,021 Euro und damit -12,77 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOBE SCIENCES LTD finden Sie auf Wallstreet Online.